News

Sana Biotechnology Announces Positive Six-Month Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression

Sana Biotechnology, a company focused on changing the possible for patients through engineered cells, today announced six-month follow-up results from an investigator-sponsored, first-in-human study transplanting UP421, an allogeneic primary islet cell therapy engineered with Sana’s hypoimmune (HIP...

Neurona Announces Publication in Neuron Reporting Durable Preclinical Engraftment of Human Interneuron Cell Therapy

Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for disorders of the nervous system, today published a new peer-reviewed study in Neuron, a Cell Press journal, titled “Human stem cell-derived GABAergic interneuron development reveals early...

Biotia Partners with Leading Korean Pharmaceutical Company to Advance Infectious Disease Diagnostics in Remote Regions -- Including in Space

Biotia, a biotechnology company pioneering the development of novel infectious disease diagnostics, today announced its selection as an awardee in the Humans in Space (HIS) Challenge, a global innovation program led by South Korea–based Boryung Corporation.

First Patient Enrolled in Aclarion’s Groundbreaking CLARITY Trial

Aclarion, a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the first patient enrollment in the CLARITY (C hronic L ow b A ck pain R andomized I ...

Amplified Sciences Secures Exclusive Patent License from UCSF for Cutting-Edge Diagnostic Technology

Amplified Sciences announced on June 14th that it has secured an exclusive global license to a patent from the University of California, San Francisco (UCSF) that helps enable PanCystPro, the company’s first product offered as a Lab Developed Test in their CLIA laboratory. We congratulate UCSF...

Neurona Doses First Patient in Phase 1/2 Trial of NRTX-1001 Cell Therapy in Adults with Drug-Resistant, Bilateral Mesial Temporal Lobe Epilepsy (MTLE)

Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for disorders of the nervous system, today announced dosing of the first patient in its Phase 1/2 clinical trial of NRTX-1001 cell therapy in adults with drug-resistant bilateral mesial temporal...

Born in California and Innovator Awards 2025

University of California ventures were center stage at the 2025 Born in California event, held May 5 at the Cove at UC Irvine’s Beall Applied Innovation. The event brought together 20 startups from all 10 University of California campuses and drew more than 200 attendees, including investors,...

Montara Therapeutics to Develop Novel Treatments Using the BrainOnly™ Platform with Grant from The Michael J. Fox Foundation

Montara Therapeutics, a biotech company pioneering brain-selective therapies for central nervous system (CNS) diseases, today announced it has received a research grant from The Michael J.

BeeKeeperAI and cStructure Collaborate to Advance Causal AI for Scientific Advancement and Healthcare Innovation

BeeKeeperAI, a pioneer in privacy-enhancing, multi-party collaboration software for AI development and deployment, and cStructure, a leading innovator in collaborative causal inference, today announced a collaboration for advancing causal AI to speed up the ability of scientists, health data...

New Data Show Delve Bio’s Metagenomic Platform Accurately Identifies Viruses and Their Subtypes With a Single Test

Delve Bio, a pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, today announced data showing that its groundbreaking infectious disease test, Delve Detect, is also capable of viral subtyping for select pathogens from sequence data analyzed through its proprietary...